Fish Oil's Heart Health Benefits Clash With Australia's Access Barriers

Fish oil, widely known as omega-3, remains one of the most popular dietary supplements worldwide. Derived from oily fish, it contains essential polyunsaturated fatty acids—EPA and DHA—that play a key role in heart health and cell function. While often promoted for broader benefits like mood support and inflammation reduction, its most established use is in lowering triglycerides.

Scientific interest in fish oil grew significantly in the 1970s after researchers uncovered its heart-protective properties. Since then, studies have shown that omega-3s help maintain flexible cell membranes and reduce triglyceride levels, though a 2023 review confirmed that meaningful effects require a daily intake of over 2 grams of combined EPA and DHA.

For most people, fish oil is safe, but mild side effects such as a fishy aftertaste, nausea, or diarrhoea can occur. Beyond heart health, it has been linked to modest improvements in inflammatory conditions like arthritis, easing joint tenderness and morning stiffness. Some evidence also suggests it may help reduce symptoms of clinical depression when used alongside antidepressants.

In Australia, high-dose prescription EPA products like Vazkepa gained approval from the TGA in October 2024. However, by early 2026, availability remained limited due to ongoing negotiations over PBS reimbursement. This has restricted access for high-risk cardiovascular patients, with doctors recommending it mainly for statin-intolerant cases—though high out-of-pocket costs continue to pose a barrier.

Fish oil's reputation as a versatile supplement stems from its proven benefits for heart health and potential anti-inflammatory effects. Yet, while widely available, its prescription-grade forms face supply challenges in Australia. For those considering it, balancing evidence-based benefits with practical accessibility remains key.